EGFR and non-small cell lung carcinoma: In 2020, the China Food and Drug Administration granted approval for the use of almonertinib in treating advanced NSCLC patients with T790M-mutant EGFR who had developed resistance to first- and second-generation EGFR TKIs like gefitinib and afatinib [167].